NCT07722169Not yet recruiting
Telerehabilitation in Alzheimer's Disease
Home-based Virtual Reality Cognitive Training as an add-on to Telerehabilitation in Alzheimer's Disease: Validation of a Protocol to Slow Down Cognitive Decline and Reduce Caregivers' Burden
Source: ClinicalTrials.gov · Last updated 3 Aug 2026
Brief summary (registry, in English)
Telemedicine has developed rapidly during the COVID-19 pandemic and is now integrated into the clinical practice of many hospitals. Telemedicine offers many advantages, and even after the end of the pandemic, many patients still choose to undergo healthcare visits remotely. However, the rapid expansion of telemedicine may be associated with the risk of providing patients with unvalidated and uncontrolled telehealth solutions, potentially negatively impacting their health. In this study, the researchers aim to investigate the effectiveness of remote cognitive training in patients with mild-to-moderate Alzheimer's disease (AD) using tablets equipped with virtual reality-based cognitive exercises. The investigators also aim to evaluate the impact of online supervision of cognitive training by a neuropsychologist and to compare the costs and burden of home-based versus hospital-based cognitive training in patients with AD. This project will define the optimal modalities for cognitive telerehabilitation to ensure validated protocols for the continuity of care in AD.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 3 Jul 2026
- Start date
- Oct 2026
- Primary completion date
- Oct 2029
- Lead sponsor
- IRCCS San Raffaele
- Diseases
- Alzheimer disease
- NCT number
- NCT07722169
What you commit to
- Study type: Interventional
- Planned participants: 48
- From Oct 2026 to the primary completion date, Oct 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of psychotropic medications that may interfere with neuropsychological assessment or study treatment.
- Concurrent participation in another interventional pharmacological clinical trial.
- Use of psychotropic medications that may interfere with neuropsychological assessment.
Other illness
- History of psychiatric disorders.
- Significant cerebrovascular disease.
- Severe visual or hearing impairment that could interfere with study procedures.
- Major depressive disorder.
- History of psychiatric disorders.
- Major depressive disorder.
Other
- Refusal or inability to provide written informed consent.
- Psychosis.
- Alcohol or substance abuse.
- Any contraindication to undergoing EEG recording.
- Refusal or inability to provide written informed consent.
- Alcohol or substance abuse.
Who the study is looking for
- Age between 50 and 90 years.
- Diagnosis of Alzheimer's disease according to established diagnostic criteria.
- Mini-Mental State Examination (MMSE) score between 18 and 24.
- Stable pharmacological treatment for at least 3 months before enrolment.
- Ability and willingness to provide written informed consent.
- Age ≥18 years.
- Availability to assist the patient throughout the study.
- Ability and willingness to provide written informed consent.
Age in the registry: 50 years to 90 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.